Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

Daniel J. Landsburg, MD, Edward A. Stadtmauer, MD, Alison W. Loren, MD, Steven C. Goldstein, MD, Noelle V. Frey, MD, Sunita D. Nasta, MD, David L Porter, MD, Donald E Tsai, MD PhD, Alexander E Perl, MD, Elizabeth Hexner, MD, Selina Luger, MD

Blood (2012) 120 (21): 2600.

https://doi.org/10.1182/blood.V120.21.2600.2600

Published: 2012

Journal Articles

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Noelle V. Frey, MD, Elizabeth O. Hexner, MD, David L Porter, MD, James K. Mangan, MD, PhD, Alison W. Loren, MD, Joseph Hatem, MD, Adam Bagg, MD, Alexander E Perl, MD, Donald E Tsai, MD PhD, Courtney D. DiNardo, MD, Daniel Heitjian, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 3576.

https://doi.org/10.1182/blood.V120.21.3576.3576

Published: 2012

Journal Articles

Posttransplant Lymphoproliferative Disorder in Kidney Transplant Patients: A Report of 68 Cases

Kathleen J Tsai, Jonathan H Bloom, Ran Reshef, MD, Deirdre Sawinski, MD, Melissa Bleicher, MD, Simin Goral, MD, Robert Grossman, MD, Donald E Tsai, MD PhD, Roy D Bloom, MD

Blood (2011) 118 (21): 2662.

https://doi.org/10.1182/blood.V118.21.2662.2662

Published: 2011

Journal Articles

Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.

Ran Reshef, MD, Saran Vardhanabhuti, MS, Marlise R Luskin, MD, Daniel F Heitjan, PhD, David L Porter, MD, Edward A Stadtmauer, MD, Donald E Tsai, MD, PhD

Blood (2009) 114 (22): 103.

https://doi.org/10.1182/blood.V114.22.103.103

Published: 2009

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

Ran Reshef, MD, Alicia K. Morgans, MD, Nicklas R. Pfanzelter, MD, Roy D. Bloom, MD, Susan C. Brozena, MD, Vivek N. Ahya, MD, Kim M. Olthoff, MD, Donald E. Tsai, MD, PhD

Blood (2008) 112 (11): 2823.

https://doi.org/10.1182/blood.V112.11.2823.2823

Published: 2008

Journal Articles

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, MD, PhD, Melissa Potuzak, BS, Anthony Mato, MD, Alison Wakoff Loren, MD, MS, David Porter, MD, Edward A. Stadtmauer, MD, Steven Goldstein, MD, Alexander Perl, MD, Cezary Swider, BS, Adam Bagg, MD, Emile Youssef, MD, PhD, Selina Luger, MD

Blood (2008) 112 (11): 4040.

https://doi.org/10.1182/blood.V112.11.4040.4040

Published: 2008

Journal Articles

Gene Expression Analysis of Bexarotene Differentiated Acute Myeloid Leukemias Identifies Known and Novel Gene Targets.

Patricia Vanessa Sanchez, PhD, Reid P Bissonnette, PhD, Donald E Tsai, MD, PhD, Martin Carroll, MD

Blood (2008) 112 (11): 1199.

https://doi.org/10.1182/blood.V112.11.1199.1199

Published: 2008

Journal Articles

Serum Lactic Acid (LA) as a Predictor of Septic Shock in Patients with Hematologic Malignancies (HM) Who Develop Febrile Neutropenia

Anthony R Mato, MD, Selina Luger, MD, Alison W. Loren, MD, Daniel F Heitjan, PhD, Erin R. Olson, MD, Chaitra S Ujjani, MD, Samantha Jacobs, MD, Payal D. Shah, BS, Andrea N. Miltiades, BS, David Wang, MS, Kevin Lux, MS, Elise Chong, BS, Laura L Belby, BS, Donald E. Tsai, MD, Barry D. Fuchs, MD

Blood (2008) 112 (11): 666.

https://doi.org/10.1182/blood.V112.11.666.666

Published: 2008

Journal Articles

Posttransplant Lymphoproliferative Disorder in Adult Lung Transplant Recipients: A Report on Twenty-Seven Patients.

Sophie D. Stein, MD, Jamal Misleh, MD, Vivek Ahya, MD, Robert Kotloff, MD, Jason Christie, MD, Donald E. Tsai, MD, PhD

Blood (2007) 110 (11): 4425.

https://doi.org/10.1182/blood.V110.11.4425.4425

Published: 2007

Journal Articles

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Donald E. Tsai, MD, PhD, Selina Luger, MD, Allison Kemner, RN, Alison W. Loren, MD, Cezary Swider, PhD, Ami Goradia, MD, Charalambos Andreadis, MD, Richard G. Ghalie, MD, James Thompson, MD, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Alexander Perl, MD, Adam Bagg, MD, Steven Goldstein, MD, Martin Carroll, MD

Blood (2006) 108 (11): 1955.

https://doi.org/10.1182/blood.V108.11.1955.1955

Published: 2006

Journal Articles

Treatment of Post-Transplant Lymphoproliferative Disorder (PTLD) with Rituximab or Chemotherapy: The University of Pennsylvania Experience.

Rebecca L. Elstrom, MD, Charalambos Andreadis, MD, Nicole Aqui, MD, PhD, Donald E. Tsai, MD, PhD

Blood (2005) 106 (11): 936.

https://doi.org/10.1182/blood.V106.11.936.936

Published: 2005

Journal Articles

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Dan T. Vogl, MD, Selina Luger, MD, David L. Porter, MD, Elise A. Chong, Stephen J. Schuster, MD, Donald E. Tsai, MD, Alexander Perl, MD, Alison W. Loren, MD, MS, Stephen Goldstein, MD, Sunita D. Nasta, MD, Charalambos Andreadis, MD, Patricia A. Mangan, Kimberly Hummel, Donald L. Siegel, MD, PhD, Eli Glatstein, MD, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1171.

https://doi.org/10.1182/blood.V106.11.1171.1171

Published: 2005

Journal Articles

Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases.

Himisha Patel, MD, Dan Vogl, MD, Nicole Aqui, MD, Edward A. Stadtmauer, MD, Kim Olthoff, MD, Donald E. Tsai, MD, PhD

Blood (2005) 106 (11): 1507.

https://doi.org/10.1182/blood.V106.11.1507.1507

Published: 2005

NARROW

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Posttransplant Lymphoproliferative Disorder in Kidney Transplant Patients: A Report of 68 Cases

Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Gene Expression Analysis of Bexarotene Differentiated Acute Myeloid Leukemias Identifies Known and Novel Gene Targets.

Serum Lactic Acid (LA) as a Predictor of Septic Shock in Patients with Hematologic Malignancies (HM) Who Develop Febrile Neutropenia

Posttransplant Lymphoproliferative Disorder in Adult Lung Transplant Recipients: A Report on Twenty-Seven Patients.

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Treatment of Post-Transplant Lymphoproliferative Disorder (PTLD) with Rituximab or Chemotherapy: The University of Pennsylvania Experience.

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only